Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

ClinicalTrials.gov ID: NCT02656069

Public ClinicalTrials.gov record NCT02656069. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

G-Pen (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adult Patients With T1DM: A Phase 3, Multi-center, Randomized, Blinded, 2-Way Crossover Study to Evaluate Efficacy and Safety

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a blinded, randomized crossover study to compare the safety and efficacy of G-Pen (glucagon injection) to Lilly Glucagon (glucagon for injection \[rDNA origin\]) for hypoglycemia rescue of adult patients with type 1 diabetes.

Study identification

NCT ID: NCT02656069
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Xeris Pharmaceuticals; Industry
Enrollment: 80 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 15, 2017 (Actual)
Primary completion: Aug 14, 2017 (Actual)
Completion: Sep 25, 2017 (Actual)
Last update posted: Oct 30, 2018

2017

United States locations

U.S. sites: 6
U.S. states: 4
U.S. cities: 6

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham	Birmingham	Alabama	35294	—
ProSciento, Inc.	Chula Vista	California	91911	—
AMCR Institute	Escondido	California	92025	—
Diablo Clinical Research	Walnut Creek	California	94598	—
Clinical Trials of Texas, Inc.	San Antonio	Texas	78229	—
Rainier Research	Renton	Washington	98057	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02656069, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 30, 2018 · Synced Oct 23, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02656069 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →